B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets.

ABSTRACT: Increasing recognition of the role of B cells in the adaptive immune response makes B cells an important therapeutic target in autoimmunity. Numerous current and developmental immunotherapies target B cells for elimination through recognition of cell-surface proteins expressed specifically on B cells, in particular CD19 and CD20. Similarities and differences in the function and expression of these two molecules predict some shared, and some distinct, pharmacological effects of agents targeting CD19 versus CD20, potentially leading to differences in the clinical safety and efficacy of such agents. Here, we review current knowledge of CD19 and CD20 function and biology, survey current and developmental therapies that target these molecules, and discuss potential differences in elimina

SUBMITTER: Forsthuber TG 

PROVIDER: S-EPMC5865455 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature